Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine in Treatment Resistant Depression
NCT06480201Phase 1Recruiting
- Sponsor
- Texas A&M University
- Start
- Jan 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of ketamine in treatment-resistant depression (TRD) and major depressive disorder (MDD) (3 arms), sponsored by Texas A&M University. Primary endpoints: Resting State Gamma Power, Auditory Steady State Response Gamma Power and 1 more. Started Jan 2024; status: recruiting.
02
Drugs
ketamine
03
Conditions
treatment-resistant depression (TRD)major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06480201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06480201.